Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.26142 http://scihub22266oqcxt.onion/10.1002/jmv.26142 32510169!7300876!32510169     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2020 ; 92 (11): 2702-2708 Nephropedia Template TP {{tp|p=32510169|t=2020. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19 |pdf=|usr=}}{{32510169}} gab.com Text A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19 JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32510169 #FOAvip This study aims to explore the clinical effect of Arbidol (ARB) combined with adjuvant therapy on patients with coronavirus disease 2019 (COVID-19). The study included 62 patients with COVID-19 admitted to the First Hospital of Jiaxing from January to March 2020, and all patients were divided into the test group and the control group according to whether they received ARB during hospitalization. Various indexes in the two groups before and after treatment were observed and recorded, including fever, cough, hypodynamia, nasal obstruction, nasal discharge, diarrhea, C-reactive protein (CRP), procalcitonin (PCT), blood routine indexes, blood biochemical indexes, time to achieve negative virus nucleic acid, and so on. The fever and cough in the test group were relieved markedly faster than those in the control group (P < .05); there was no obvious difference between the two groups concerning the percentage of patients with abnormal CRP, PCT, blood routine indexes, aspartate aminotransferase, and alanine aminotransferase (P > .05); the time for two consecutive negative nucleic acid tests in the test group were shorter than that in the control group; the hospitalization period of the patients in the test group and control group were (16.5 +/- 7.14) days and (18.55 +/- 7.52) days, respectively. ARB combined with adjuvant therapy might be able to relieve the fever of COVID-19 sufferers faster and accelerate the cure time to some degree, hence it's recommended for further research clinically. Twit Text FOAVip A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19 ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32510169 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32510169 #FOAvip English Wikipedia <ref>{{Cite pmid|32510169}}</ref> A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19 #MMPMID32510169 Chen W; Yao M; Fang Z; Lv X; Deng M; Wu Z J Med Virol 2020[Nov]; 92 (11): 2702-2708 PMID32510169show ga This study aims to explore the clinical effect of Arbidol (ARB) combined with adjuvant therapy on patients with coronavirus disease 2019 (COVID-19). The study included 62 patients with COVID-19 admitted to the First Hospital of Jiaxing from January to March 2020, and all patients were divided into the test group and the control group according to whether they received ARB during hospitalization. Various indexes in the two groups before and after treatment were observed and recorded, including fever, cough, hypodynamia, nasal obstruction, nasal discharge, diarrhea, C-reactive protein (CRP), procalcitonin (PCT), blood routine indexes, blood biochemical indexes, time to achieve negative virus nucleic acid, and so on. The fever and cough in the test group were relieved markedly faster than those in the control group (P < .05); there was no obvious difference between the two groups concerning the percentage of patients with abnormal CRP, PCT, blood routine indexes, aspartate aminotransferase, and alanine aminotransferase (P > .05); the time for two consecutive negative nucleic acid tests in the test group were shorter than that in the control group; the hospitalization period of the patients in the test group and control group were (16.5 +/- 7.14) days and (18.55 +/- 7.52) days, respectively. ARB combined with adjuvant therapy might be able to relieve the fever of COVID-19 sufferers faster and accelerate the cure time to some degree, hence it's recommended for further research clinically. |*COVID-19 Drug Treatment[MESH] |Adjuvants, Pharmaceutic/*therapeutic use[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Antiviral Agents/*therapeutic use[MESH] |Child[MESH] |Child, Preschool[MESH] |Cough/drug therapy[MESH] |Female[MESH] |Fever/drug therapy[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Indoles/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Treatment Outcome[MESH]A study on clinical effect of Arbidol combined with adjuvant therapy o(epmc).pdf DeepDyve Pubget Overpricing